Pfizer Share Analysis:

Are you searching for expert opinions and easy-to-understand analysis on Pfizer share? This blog covers everything you need to know—from technical signals to strong fundamentals—about Pfizer Ltd, with our bullish target of Rs 8000 for this top pharma stock.

Technical Analysis of Pfizer Share

Pfizer share has recently shown encouraging signs both on the daily and weekly charts. Let’s break down the technical signals:

The daily chart of Pfizer share displays the price action over recent months, highlighted with:

• Cup and Handle Pattern: Both daily and weekly charts showcase a classic “cup and handle” pattern, often viewed as a bullish continuation signal. The stock has formed a rounded base and is approaching its resistance zone around Rs5987.

• Volume Support: Increasing volume alongside the price rise points to genuine buying interest and accumulation.

• Moving Averages: The share price is trading above key moving averages (Green: 200 EMA, Red: 100 EMA), indicating strength and potential upward momentum.

• Resistance Level: If Pfizer share convincingly breaks and holds above Rs5987, there’s potential for a swift move towards Rs8000 based on pattern projections and historical resistance.

The weekly chart of Pfizer share shows a longer-term perspective:

• Extended Cup & Handle Formation: This pattern repeats on the weekly chart, suggesting bigger upside possibilities if the Rs5987 resistance is decisively breached.

• Stronger Confirmation: Weekly patterns hold more weight for investors. Combined with healthy volume and moving averages, it supports a bullish view.

Pfizer Ltd stands out as one of India’s top pharma companies, backed by world-class parentage and robust product diversification.

Company Overview

• Subsidiary of Pfizer Inc., a global pharma leader present in 125+ countries.

• Engaged in manufacturing, marketing, trading, and export of a wide range of pharmaceutical products in India.

• Operates both through its own facilities and contract manufacturing partners.

Product Portfolio & Market Position

• Offers 125+ products across 15 therapeutic areas (Vaccines, Internal Medicine, Hospital Business, Inflammation & Immunology, etc.).

• Pioneer in Pneumococcal Vaccines with a market share of 52% (units) and 64.8% (value) as of March 2024.

• Corex Dx leads the dry cough space with a 15% share.

Distribution & Reach

• Pfizer share benefits from an extensive network: 200,000+ healthcare providers, 1,800+ hospitals, 250,000+ pharmacies, and reaches 300 million patients yearly.

• The Duty50 Initiative has made notable progress in adult vaccinations.

Manufacturing Strength

• Goa facility produces 3.6 billion tablets yearly, with 70% business operations manufactured in India.

• Collaborates with 18 CMOs for diversified production of top brands like Becosules, Gelusil, Corex DX.

Warehousing

• Manages logistics across 15 partners, handling approx. 6.8 billion units annually.

Financial Highlights

• Market Cap: ₹24,374Cr

• Current Price: ₹5,328

• Stock P/E: 36.1 (vs. Industry PE: 33.1)

• Book Value: ₹922

• Dividend Yield: 0.66%

• ROCE: 21.6%

• ROE: 16.4%

• Reserves: ₹4,172Cr

• Borrowings: ₹41Cr (very low debt)

Growth Metrics

 

Shareholding Pattern

• Promoters: 63.92%

• FIIs: 2.40%

• DIIs: 17.23%

• Public: 16.45%

Recent Developments

• Voluntary recall of some products impacted revenue (-16% from FY22-FY24); driven by strict adherence to quality standards.

• Divested Thane property for ₹264Cr to Zoetis, boosting reserves.

Why Pfizer Share Can Reach Rs8000

• Strong Technical Setup: Patterns and moving averages show bullish momentum with potential for a breakout above Rs5987, aiming for Rs8000.

• Robust Fundamentals: Low debt, strong promoter holding, leadership in key pharma segments, and resilient operational metrics.

• Brand & Scale: Backing by international parent and vast distribution ensure continued leadership and market expansion.

Conclusion

Pfizer share combines technical bullishness and fundamental strength, making it a top pick for long-term investors aiming for substantial returns. With a clear path to Rs8000, strong management, and brand power, Pfizer Ltd presents an attractive buy opportunity in India’s pharma sector.

For more Info : visit

For HDFC Life share analysis : visit